News Archive

SANTA CLARA, Calif., Jan. 7, 2020 /PRNewswire/ — Based on its recent analysis of the global single-cell analysis market, Frost & Sullivan recognizes LumaCyte, LLC (LumaCyte) with the 2019 Global New Product Innovation Award for its groundbreaking Laser Force Cytology™ (LFC™) technology. The solution accelerates therapies and analytical insights by enabling new cell discovery, characterization and phenotyping across broad applications. LumaCyte’s recently launched flagship platform, Radiance®, is an automated, high-content, label-free single-cell analysis and sorting platform. LFC™ helps labs and biopharmaceutical organizations cost-effectively optimize viral quantification for example, which are critical assays for vaccine and cell and gene therapy development and production, leading to easier sample preparation, shortened detection time, and high-quality, objective data.

GAITHERSBURG, Md., Jan. 09, 2020 (GLOBE NEWSWIRE) — NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that industry veterans Han Myint, MD, and John Trainer, MBA, have been appointed as the Company’s Chief Medical Officer and Chief Financial Officer, respectively.

Dr. Myint commented, “I am very excited to join NexImmune at such a time where I can leverage my professional experience to oversee the Company’s first two clinical trials for NEXI-001 and NEXI-002 in patients with relapsed forms of Acute Myeloid Leukemia (AML) and Multiple Myeloma, respectively. The Company has developed a novel technology that directs endogenous T cells against multiple tumor antigen targets. For patients suffering from a variety of cancers, I believe this approach has the potential to deliver potent anti-tumor activity while minimizing potential off-target toxicities, and I am looking forward to working with team to make this a reality for these patients.”

Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® REIT, is the first and longest-tenured owner, operator, and developer uniquely focused on collaborative life science, technology , and agtech campuses in AAA innovation cluster locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in life science, technology, and agtech campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success.

The University of Maryland School of Pharmacy welcomed nearly 200 researchers from across the University of Maryland, Baltimore (UMB) and Johns Hopkins University (JHU) to the second UMB-JHU Joint Symposium on Drug Discovery on Dec. 3. Organized by Paul Shapiro, PhD, professor and chair of the Department of Pharmaceutical Sciences (PSC) at the School of Pharmacy, and Barbara Slusher, MAS, PhD, professor of neurology at the Johns Hopkins University School of Medicine and director of Johns Hopkins Drug Discovery, the symposium provided an open forum for scientific exchange and interactive communication among students, postdoctoral fellows, and faculty from two of Baltimore’s preeminent academic institutions.

Image: Nearly 200 researchers from across UMB and JHU gather for the second Joint Symposium on Drug Discovery. – https://www.umaryland.edu

ROCKVILLE, Md. & FOSTER CITY, Calif. & HANGZHOU, China–(BUSINESS WIRE)–Jan. 6, 2020– GlycoMimetics, Inc. (NASDAQ: GLYC), a leader in the field of applied glycotechnology for cancer, and Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies, announced today an exclusive collaboration and license agreement for the development and commercialization of uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China.

The largest biotechnology incubator of its kind in New York City has opened at 180 Varick Street in Hudson Square.

BioLabs @ NYULangone is designed to attract the nation’s most innovative companies working in early stage life sciences.

The co-working facility currently has 22 companies and is expected to house more than 40 early-stage biotechnology and life sciences companies, 160 scientists, business personnel and support staff, in 50,000 s/f of newly renovated and fully equipped laboratory and office space.

Image: Lieutenant Governor Kathy Hochul joins representatives of NYCEDC, NYU Langone Health and BioLabs at the official opening. – https://rew-online.com

President Moon Jae-in announced in May that the government would designate the biohealth industry as one of the three new sectors for future growth, help the industry account for at least 6 percent of the global pharmaceutical and medical device market share by 2030, achieve $50 billion biohealth exports, and nurture the sector as one of the five major export industries.

The announcement came during his visit to Osong, North Chungcheong Province, which has a cluster of biotech research firms.

Image: http://www.koreabiomed.com

Scientists from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) this week proposed a new theory, based on the findings of three previously published studies, to improve the efficacy and safety of immunotherapy drugs. The theory calls for a new design for these drugs that would prevent side effects like life-threatening immune system reactions and enable a higher dose of the drug to be administered.

Image: https://www.umaryland.edu

The Maryland Technology Development Corp. and the National Institute of Standards and Technology awarded four companies a total of $448,000 to develop NIST-licensed technologies for the market, TEDCO announced Tuesday.

The NIST Science and Technology Entrepreneurship Program (N-STEP) focuses on commercializing NIST research. It lets NIST researchers who have left the agency or will soon be leaving the agency to commercialize technology they researched.

Image: Money, money. In this Sept. 24, 2013, file photo, freshly cut stacks of $100 bills make their way down the line at the Bureau of Engraving and Printing Western Currency Facility in Fort Worth, Texas. (AP Photo/LM Otero, File)

Eight months after Maryland Technology Development Corp. halted investments through some of its funds, the state-backed organization announced Friday it is ready to accept new applications from startups seeking investment.

TEDCO has launched a new online application process for several of its funding programs: the Rural Business Innovation Initiative, Builder Fund, Seed Fund and Maryland Venture Fund (MVF). New investments through these programs have been on hold since June, while TEDCO has enacted legislature-directed reforms prompted by a damaging audit report aimed particularly at the MVF.